Abhik Mukherjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8056429/publications.pdf

Version: 2024-02-01

1040056 1058476 1,604 16 9 14 citations g-index h-index papers 16 16 16 4489 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	12.8	1,221
2	Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Molecular Oncology, 2014, 8, 1326-1338.	4.6	109
3	<scp>HER</scp> 2 challenge contest: a detailed assessment of automated <scp>HER</scp> 2 scoring algorithms in whole slide images of breast cancer tissues. Histopathology, 2018, 72, 227-238.	2.9	102
4	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma <i>in situ</i> . Histopathology, 2017, 71, 258-268.	2.9	58
5	Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 2017, 164, 317-325.	2.5	22
6	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. British Journal of Cancer, 2017, 117, 1176-1184.	6.4	16
7	Repurposing Antibacterial AM404 As a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells. Cancers, 2020, 12, 106.	3.7	15
8	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. Modern Pathology, 2018, 31, 1675-1682.	5.5	13
9	Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterology, 2021, 21, 244.	2.0	12
10	Chemokine (C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology: Clinical Research, 2017, 3, 105-114.	3.0	9
11	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British Journal of Cancer, 2018, 118, 1142-1151.	6.4	9
12	Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells. Cancer Research and Treatment, 2021, 53, 457-470.	3.0	9
13	Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids. Oncogenesis, 2022, 11, 4.	4.9	6
14	In vitro cytotoxicity of Phortress against colorectal cancer. International Journal of Oncology, 2006, 29, 1287-94.	3.3	3
15	Evaluation of flap endonuclease-1 (FEN1) as a prognostic, predictive, and therapeutic target in breast (BC) and ovarian cancer (OVC) Journal of Clinical Oncology, 2013, 31, 1016-1016.	1.6	0
16	Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC) Journal of Clinical Oncology, 2015, 33, 1040-1040.	1.6	0